Discovery Minerals LTD (DSCR): Tax selling brings it up...LOL

Play Episode

7min

Proactive - Interviews for investors

Nexus Minerals expands Payns Find gold target

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Proactive - Interviews for investors

VSPC expansion plans detailed by Livium CEO

Livium Ltd CEO Simon Linge talked with Proactive about the company's progress on its lithium ferro phosphate (LFP) demonstration plant and strategic growth plans. The company is working to secure the remaining A$30.00 million to fully fund the plant, with Linge stating that the process involves "complex transactions" and that "there's a bit to be thought through". The funding includes support from a substantial A$30.00 million grant from the Australian Renewable Energy Agency (ARENA), which covers around 50% of the facility’s estimated build and operational costs. Linge said the grant acts as both financial support and validation of Livium’s VSPC technology, which is positioned as leading-edge and referred to in China as Generation 4 LFP. He highlighted that demand from potential customers already exceeds the plant’s expected capacity, and the company is selectively targeting energy storage and electric vehicle sectors. In the US, Livium is working closely with distributor United Mineral & Chemical Corporation (UMC), which has already introduced the business to new clients and OEMs. Linge said UMC's presence provides "boots on the ground" support, crucial for US market penetration. The company continues to evaluate whether to expand through licensing or direct operations, based on proximity to clients and local market conditions. 📺 For more insightful interviews, visit [Proactive's YouTube channel](https://www.youtube.com/@ProactiveInvestors). Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #Livium #VSPC #LithiumIronPhosphate #BatteryMaterials #EnergyStorage #EVBatteries #ARENAgrant #CleanEnergy #TechInnovation #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Data security: archTIS lands key licensing deal

archTIS Ltd CEO and Managing Director Daniel Lai talked with Proactive about a newly signed $390,000 licensing agreement with a major Japanese multinational. The deal builds on archTIS’s acquisition of Direktiv and its integration of advanced cybersecurity technology into its Trusted Data Integration platform. Lai explained that the licensing agreement enables the Japanese company—an asset services provider with operations valued at $12.5 billion—to introduce new data-centric security services into the Japanese market. “This is just another example of that occurring, which is really exciting for the company,” Lai said, referring to archTIS’s broader international expansion strategy. He noted that the company had always planned to replicate its success with the Australian Department of Defence and local defence industrial base in overseas markets, particularly those facing geopolitical pressures. Lai also highlighted progress in the US and Europe, where trials were recently completed with a large US department and NATO in the UK. Looking ahead, he remained “quietly optimistic” about meeting financial targets by June 30 and delivering further material updates to the market. He acknowledged market timing and election cycles as influencing deal flow, but said government and intelligence agency engagement continues to build momentum. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #archTIS #Cybersecurity #DataSecurity #LicensingDeal #JapaneseMarket #QuadAlliance #TrustedDataIntegration #GlobalExpansion #DefenseTechnology #ProactiveInvestors

Followers	391
Posts	26015
Boards Moderated	2
Alias Born	01/23/2002

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

DSCR Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free